Skin response to ultraviolet B light in patients infected with human immunodeficiency virus.

Type:Uv phototherapy Time:2017-11-08 9:07:10

Photosensitivity disorders have been reported in human immunodeficiency virus (HIV)-infected patients, often as the

initial manifestation of the disease. The objective of this study was to evaluate whether the HIV-infected population

demonstrates increased sensitivity to ultraviolet B (UVB) radiation. Minimal erythema dose values to UVB (MED-B) of 57

consecutive HIV-infected patients were compared to those of a control group of 57 consecutive patients with skin

diseases, who were otherwise healthy and had no risk factors for HIV infection. MED-B determinations were performed in

all individuals prior to the initiation of phototherapy for treatment of skin disease. None of the patients had a

history of photosensitivity. Furthermore, the mean levels of the highest UVB doses received by each group during the

treatment courses were compared. The mean age of the HIV-infected cohort was 43 years (range 26-61 years). The mean

MED-B for this group was 82.8 +/- 3.8 (SEM) mJ/cm2. The mean age of the control group was 45 years (range 24-77

years), and their mean MED-B was 81.0 +/- 3.8 (SEM) mJ/cm2. After 12 weeks of treatment, one HIV-infected patient

developed photosensitivity associated with a decreased MED-B value. The mean level of the highest UVB doses received

by the HIV-infected group [427.5 +/- 67.2 (SEM) mJ/cm2] was lower than that received by the control group [640.8 +/-

65.9 (SEM) mJ/cm2], since HIV-infected patients received fewer treatments (mean: 34.7 treatments per patient) than the

patients in the control group (mean: 65.6 treatments per patient). These data indicate that the HIV-infected patient

population, without history of photosensitivity, does not show increased sensitivity to UVB light as determined by

MED-B values.

www.kerneluvb.com----The leader manufacturer of UVB Phototherapy.